奥扎格雷钠联合血栓通治疗急性脑梗死疗效观察

目的 观察奥扎格雷钠联合血栓通注射液治疗急性脑梗死的疗效和安全性.方法 将127例急性脑梗死患者随机分为对照组、治疗组和联合治疗组.对照组给予长春西汀氯化钠注射液;治疗组给予奥扎格雷钠注射波;联合治疗组给予奥扎格雷钠联合血栓通注射液,各组均静脉点滴,1次/天,连续治疗14天.结果 联合治疗组在治疗后第7天、14天的神经功能缺损改善均显著优于治疗组和对照组(P<0.05):联合治疗组的总有效率为81.4%,治疗组总有效率为54.7%,对照组的总有效率为52.4%,联合治疗组总有效率与治疗组、对照组比较差异有统计学意义(P<0.05),治疗组与对照组比较差异无统计学意义(P>0.05).且未见明显副作用.结论 奥扎格雷钠联合血栓通注射液治疗急性脑梗死安全有效.

Clinical Study on the Treatment of Acute Cerebral Infraction by Combined Injection of Ozagrel and Xueshuantong

Aim To observe the clinical efficiency and safety of ozagrel sodium(OS) combined with Xueshuantong (XST) in treatment of patients with acute cerebral infraction(ACI).Methods 127 patients with acute cerebral infraction were randomly divided into control group,treatment group and combined-treatment group.The control group was given vinpocetine sodium chloride injection(VSCI).The treatment group was given OS.The combined-treatment group was given OS and XST(once a day for 14 days).All the patients were observed for the clinical efficiency and safety. Results Neurological function was significantly improved in the combined-treatment group as compared with the treated group and the control group after 7 days or 14 days of therapy(P<0.05).The total effective rate in combinedtreatment group was obviously higher than those in the treatment group and the control group(81.4%,54.7%and 52.4%,respectively P<0.05).No statistically significant difference was observed in the treatment group and the control group(P>0.05).No significant difference was observed in adverse effect in the three groups.Conclusion Ozagrel sodium combined with Xueshuantong in the treatment of patients with acute cerebral infraction is an effective and safe method.